Article

Fft.com on 2021-09-28 12:34

GSK agrees deal to develop longer-acting HIV drugs

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

GSK

Related news

FHIV treatment breakthrough boosts GSK ft.com
FHIV unit key driver of GSK growth ft.com
FGSK and CureVac to develop vaccines to tackle Covid variants ft.com
$4.2B deal: GSK and Merck KGaA to develop cancer immunotherapy bizjournals.com
GSK PLC: GSK raises forecasts after strong sales in vaccines and HIV business Financial Times
FGSK claims new HIV therapy will be less harmful ft.com
In UNC partnership, GSK does HIV/AIDS about face bizjournals.com
FGSK sees positive signs from reduced HIV treatment ft.com
FGSK drops plans for IPO of HIV drugs unit ft.com
Europe , China
MGSK gets FDA approval for HIV drug for children marketwatch.com
FGSK PLC: GSK agrees to buy respiratory medicine specialist Aiolos Bio for $1.4bn ft.com
Gilead, Merck collaborate to develop long-acting HIV treatment The Jerusalem Post (JPost.com)
MGSK and CureVac join forces to develop vaccines targeting new COVID-19 variants marketwatch.com
Belgium , Germany , Brazil , South Africa
HBritish Drugmaker GSK to Collaborate With CEPI in Effort to Develop Coronavirus Vaccine hamodia.com
Germany , France , Norway , China , Australia
Gilead pays startup $123M to develop longer-lasting HIV pill bizjournals.com
WGSK buying HIV drug pipeline from Bristol-Myers Squibb in $1.46B deal wraltechwire.com
North Carolina , Research Triangle Park
GSK buys HIV assets from Bristol-Myers for $350M up front bizjournals.com
FGSK raises profit outlook on strong vaccine and HIV drug sales ft.com